Supernus Pharmaceuticals (SUPN) Capital Leases (2020)
Supernus Pharmaceuticals (SUPN) posted quarterly Capital Leases of $19.3 million for Q3 2020.
Supernus Pharmaceuticals (SUPN) Capital Leases (2020) Analysis & Trends
Supernus Pharmaceuticals has reported Capital Leases for 1 years, with the latest figure at $19.3 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.37 Bn | 185.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 19.29 Mn |